ClinicalTrials.gg
RecruitingNCT05409482Updated May 13, 2025

A Real-world Study of Camrelizumab Combined With Apatinib Mesylate in Unresectable Hepatocellular Carcinoma

An observational study in Hepatocellular Carcinoma, sponsored by Meng Chao Hepatobiliary Hospital of Fujian Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-05-13.

Sponsored by Meng Chao Hepatobiliary Hospital of Fujian Medical University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started Aug 2022; still recruiting 4 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
300
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,314 studies in Carcinoma, Hepatocellular with a site in China — 489 open to participants now, 561 under way, 70 of them phase 3. Carcinoma, Hepatocellular · China.

Planned enrollment
121st of 275
300 · median 300
Started
2022
with 110 others
Observational
275 of 1,314
120 open now
Primary completion
2026-03
later than 217 of 560 live
Registered
720th of 1,314
by date

Among the 1,314 studies in Carcinoma, Hepatocellular with a site in China, this one is the 121st largest by planned enrollment of the 275 observational ones that give a count, is one of 111 that started in 2022, is one of 275 observational ones, reaches primary completion later than 217 of the 560 other live ones, and was the 720th registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

489 of the 1,314 studies in Carcinoma, Hepatocellular with a site in China are open now. Recruiting first, the newest first:

484 more — sign in →

All 489 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,314 studies in Carcinoma, Hepatocellular with a site in China, or all of them as a file.
02

Study summary

To evaluate the efficacy and safety of camrelizumab combined with apatinib mesylate in the treatment of unresectable hepatocellular carcinoma.

Read the detailed description

Combination therapy for patients with unresectable liver cancer is the future trend, and with the development of therapeutic drugs for liver cancer, especially molecular targeted drugs and immunotherapy drugs, the effective rate of liver cancer treatment has been significantly improved, and the treatment of unresectable liver cancer has gradually changed. possible. Therefore, for patients with unresectable liver cancer, how to choose a combined treatment plan will be an important means to improve the therapeutic effect of liver cancer, and it is also a hot spot in the field of clinical research on liver cancer in recent years.

Based on the above research background, this study is now designed as a non-intervention, selecting patients with unresectable hepatocellular carcinoma as the research subjects to analyze the efficacy and safety of camrelizumab combined with apatinib mesylate. In order to bring more long-term benefits to patients with unresectable hepatocellular carcinoma.

03

Conditions studied

  • Hepatocellular Carcinoma
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with unresectable hepatocellular carcinoma

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age: 18 years old ≤ age ≤ 75 years old, both male and female;
  2. Strictly meet the clinical diagnostic criteria of the "Guidelines for the Diagnosis and Treatment of Primary Liver Cancer" (2022 Edition) or hepatocellular carcinoma patients diagnosed by histopathological or cytological examinations , and at least one (according to the mRECIST1.1 standard, the long diameter of the measurable lesion on spiral CT scan is ≥10mm or the short diameter of the malignant lymph node is ≥15mm);
  3. Not previously accepted Patients with hepatocellular carcinoma who have progressed/intolerable and unresectable after systemic therapy or systemic therapy;
  4. CNLC stage IIb-IIIb;
  5. liver function grade A or B (5- 7 points);
  6. PS score 0-1 points;
  7. Expected survival period ≥ 12 weeks;
  8. If the patient has active virus (HBV) infection: if HBV-DNA ≤ 2000, you can start directly Treatment; if HBV-DNA>2000, antiviral treatment should be given for one week before starting treatment;
  9. The subjects volunteered to join the study, had good compliance, and cooperated with follow-up.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or breastfeeding women;
  2. Patients with to immunotherapy, including but not limited to the following: post-transplantation patients, patients with severe diseases, patients with organ failure, patients who have previously experienced adverse reactions of grade 4 or above using immunotherapy, and uncontrolled infectious diseases;
  3. Use or systemic hormone therapy within 14 days before enrollment to achieve the purpose of immunosuppression (dose>10mg/day prednisone or other equivalent hormones);
  4. It has been confirmed that camrelizumab Patients who are allergic to injections, apatinib mesylate tablets and their , or are allergic to other monoclonal antibodies;
  5. Patients with impaired consciousness or inability to cooperate with treatment, combined with mental illness;
  6. Patients who have participated in other clinical trials in the past three months;
  7. Severe liver, kidney, heart, lung, brain and other major organ failure;
  8. According to the investigator's judgment, patients with other serious concomitant diseases that endanger the patient's safety or affect the patient's completion of the study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Progression-free survival(PFS)

    PFS was defined as the subject's date from the date of the first dose to the date of the first documented tumor progression (as assessed by mRECIST criteria, with or without continuation of treatment) or the date of death from any cause, whichever occurred first.

    Time frame: Up to 2 years

Secondary outcomes

  1. Objective response rate(ORR)

    Refers to the proportion of all subjects with the best overall response (BOR) as complete remission (CR) or partial remission (PR) according to mRECIST 1.1 criteria.

    Time frame: Up to 2 years

  2. Disease control rate(DCR)

    Refers to the proportion of all subjects with the best overall response (BOR) according to mRECIST criteria as complete remission (CR), partial remission (PR) and stable disease (SD).

    Time frame: Up to 2 years

  3. Overall survival(OS)

    Defined as the time from the date of the first dose to the death of the subject from any cause.

    Time frame: Up to 8 years

  4. Occurence of AE and SAE

    Occurence of Adverse Event (AE) and Serious Adverse Event (SAE) (NCI CTCAE 5.0)

    Time frame: Up to 2 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2022 (actual). Primary completion is estimated for Mar 2026, 42 months after the start.

Of 303 non-industry observational studies under Carcinoma, Hepatocellular, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 114. This study's planned 42 months is below that.

Counting every sponsor, half of 352 studies reached it within 51 months; a quarter within 32 and three quarters within 108.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2022
First posted
Jun 8, 2022
StartActual
Aug 20, 2022
Primary completionEst.
Mar 1, 2026
CompletionEst.
Mar 1, 2026
Last update
May 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05409482
Lead sponsor
Meng Chao Hepatobiliary Hospital of Fujian Medical University
Responsible party
Yongyi Zeng (director, Meng Chao Hepatobiliary Hospital of Fujian Medical University) — Principal investigator
First posted
Jun 8, 2022
Start date
Aug 20, 2022
Primary completion
Mar 1, 2026 (estimated)
Completion
Mar 1, 2026 (estimated)
Last update
May 13, 2025

Study contacts

Yong yi Zeng
Contact
lamp197311@126.com
13805083802
Wu h Guo
study director · Mengchao Hepatobiliary Hospital, Fujian Medical University
Zhi bo Zhang
study director · First Affiliated Hospital of Fujian Medical University
Yi p Chen
study director · First Affiliated Hospital of Fujian Medical University
Ning Huang
study director · Union Hospital Affiliated to Fujian Medical University
Mao l Yan
study director · Fujian Provincial Hospital
Zhu t Fang
study director · Fujian Provincial Hospital
Hui Zhang
study director · Fujian Cancer Hospital
Xiao j Zhang
study director · The 900th Hospital of the Joint Logistics Support Force
Ling q Yan
study director · Fuqing City Hospital
Yan m Zhou
study director · The First Affiliated Hospital of Xiamen University
Yong yi Zeng
principal investigator · Mengchao Hepatobiliary Hospital, Fujian Medical University
Ping g Liu
study director · Zhongshan Hospital Affiliated to Xiamen University
Fu q Wang
study chair · Xiamen Hospital of Traditional Chinese Medicine
Bo h Zhang
study director · Zhongshan Hospital (Xiamen), Fudan University
Cong r Wang
study director · Quanzhou First Hospital
Wei Wang
study director · The Second Affiliated Hospital of Fujian Medical University
Yu f Chen
study director · Zhangzhou Hospital
Shao w Zhuang
study chair · Zhangzhou Hospital
Jian f Zhao
study director · Affiliated Hospital of Putian University
Jia f Chen
study director · Putian First Hospital
Wen l Zeng
study director · Longyan Second Hospital
Yong z Wang
study director · Sanming Second Hospital
Wen f Wu
study director · Nanping Second Hospital
Wen x Xie
study director · Fuding City Hospital
Feng Lin
study director · Ningde Mindong Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion